Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Alkem Laboratories - Outlook remains strong - ICICI Securities

Posted On: 2020-10-18 22:37:49


Alkem Laboratories' (Alkem) stock price has recently corrected ~10% despite strong Q1FY21 performance. We believe the correction was mainly due to reported decline in secondary sales data for Q2FY21 and dominance of acute portfolio (~85% of India sales), which would take longer to recover. In our view, this temporary situation caused by the lockdown has already been captured in the price. There remains a probability of positive surprise considering the strong traction in trade generics and relative outperformance against the industry in top brands like Pan, Pan D, etc. We remain positive on the long-term outlook based on sustainable growth in the domestic market and continuous scale-up in US generic business coupled with an improving margin profile. Reiterate BUY.

- Stock correction creates a value opportunity: The recent stock price correction by ~10% has been primarily due to weak growth resulting from lockdown, which however is temporary and does not have any structural or fundamental impact on the company' business, in our view. The lockdown effect over past six months (as per secondary sales data) is heightened for Alkem as its product mix is dominated by the acute portfolio. However, growth turned positive in Sep'20 and we expect it to improve in the coming months. Further, the company's top brands - Pan, Pan D, etc. - have outperformed the respective industries indicating faster recovery, which would also lead to margin improvement. Hence, we view the stock price correction as a value opportunity given the strong business fundamentals of the company.

- India business on strong footing: India formulations business contributes ~67% of total revenues and has consistently outperformed industry growth over the years. We believe FY21 could be a relatively underperforming year for Alkem due to its high dependence on acute portfolio (the most impacted by lockdown). However, there is an element of positive surprise with trade generics gaining strong traction and high demand in the vitamins portfolio. We estimate 4.4% growth in Alkem's India business in FY21E and ~12% growth in FY22E and FY23E each. We believe, cost savings witnessed in Q1FY21 would be partially sustainable and benefit Alkem more vs peers given its higher proportion of India sales.

- Outlook: We expect Alkem to register 10.0% revenue and 15.5% PAT CAGRs over FY20-FY23E with margin expansion of 280bps to 20.5%. Strong earnings growth coupled with reduced capex would aid free cashflow generation of ~Rs38bn over FY21E-FY23E. It would also drive RoE and RoCE higher to 19.7% and 18.1% respectively by FY23E.

- Valuation and risks: We marginally cut our earnings estimates by 2-4% for FY21E- FY23E to factor-in weak India growth in FY21E. We maintain Alkem as one of our top picks and reiterate BUY with a revised target price of Rs3,536/share based on 26x Sep'22E EPS (earlier Rs3,679/share). Key downside risks: regulatory hurdles and delay in product approvals in the US.

Shares of Alkem Laboratories Ltd was last trading in BSE at Rs.2650.7 as compared to the previous close of Rs. 2657.55. The total number of shares traded during the day was 891 in over 229 trades.

The stock hit an intraday high of Rs. 2674.65 and intraday low of 2630. The net turnover during the day was Rs. 2357265.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019